The team contributed to a PBAC public call for contributions to support PBS listing of teclistamab for patients who have received at least three prior lines of therapy, including a PI, an IMiD, and an anti-CD38 monoclonal antibody. An independent MRDR report was submitted to assist the PBAC in reviewing the application, focusing on patients' status on commencing fourth-line therapy. The report provides valuable real-world insights into patient characteristics, treatment patterns, and outcomes in this treatment setting, to support discussions at the meeting.